Articles: erectile-dysfunction.
-
Letter Case Reports
[Erectile dysfunction and proton pump inhibitors].
-
Int. J. Radiat. Oncol. Biol. Phys. · Mar 2000
Brachytherapy radiation doses to the neurovascular bundles.
To investigate the role of radiation dose to the neurovascular bundles (NVB) in brachytherapy-related impotence. ⋯ In the next few years, we hope to clarify the role of high NVB radiation doses on potency, by correlating NVB dose calculations with a large number of patients enrolled in an ongoing I-125 versus Pd-103 trial for early-stage patients, for whom detailed dosimetric and potency data are being collected prospectively. In the future, we anticipate that NVB doses may be incorporated into dosimetry guidelines to maximize tumor control and minimize treatment-related morbidity.
-
Int. J. Impot. Res. · Mar 2000
ReviewOral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction.
Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high affinity of phentolamine for alpha-1 and alpha-2 adrenergic receptors. Based on pharmacokinetic studies, it is suggested that 30-40 min following oral ingestion of 40 or 80 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations are sufficient to occupy the alpha-1 and -2 adrenergic receptors in erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity. ⋯ There were no severe adverse events. At 40 mg, 7.7% experienced rhinitis and fewer than 3.1% experienced any other side effect of treatment. Phentolamine is safe, well tolerated and efficacious for the treatment of erectile dysfunction.